Ketamine for OUD and Comorbid Depression (OUDCD)

Open single-group treatment study in people with opioid use disorder and comorbid depression testing feasibility and preliminary efficacy of adjunctive ketamine during methadone maintenance; enrolled participants receive six IV infusions over two weeks.

Ketamine 0.5 mg/kg IV given three times weekly (Mon/Wed/Fri) for two weeks; infusions are 40–50 minutes with up to 2 hours post-infusion observation. Outcomes include feasibility, patient acceptance, and preliminary effects on depression and methadone treatment retention.